TWST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Twist Bioscience Corp (TWST) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are positive growth trends in revenue and gross margin, the company is still operating at a net loss with declining EPS. Additionally, hedge funds are selling the stock, and there are no significant positive catalysts or recent news to drive immediate growth. Technical indicators are neutral to slightly bullish, but the lack of strong trading signals and mixed sentiment suggests holding off on investment for now.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), a positive MACD histogram (0.957), and neutral RSI (55.562). Key support and resistance levels are Pivot: 56.92, R1: 64.159, S1: 49.681. However, the pre-market price is down 0.83%, indicating slight bearish sentiment in the short term.
Revenue increased by 16.89% YoY in Q1 2026, and gross margin improved by 7.79% YoY to 52.05%. Analysts have raised price targets recently, citing growth potential in AI-driven drug discovery and life sciences tools.
Net income declined by 3.44% YoY, and EPS dropped by 5.66% YoY. Hedge funds are selling heavily, with a 634.68% increase in selling activity last quarter. No recent news or significant events to act as immediate growth catalysts.
In Q1 2026, revenue grew to $103.7M (+16.89% YoY), but net income dropped to -$30.51M (-3.44% YoY), and EPS fell to -0.5 (-5.66% YoY). Gross margin improved to 52.05% (+7.79% YoY), indicating operational efficiency gains.
Analysts are generally bullish, with multiple firms raising price targets to $55-$56 and maintaining Buy or Outperform ratings. However, sentiment is cautious, with risks acknowledged in the life sciences sector.
